Lexaria Bioscience Corp. (NASDAQ: LEXX) Celebrates Productive Year for Blood Pressure Drug Solution with Eye on Advancing Clinical Studies in 2022
Lexaria Bioscience’s ongoing human clinical studies for its patented and trademarked DehydraTECH technology have yielded progressively optimistic results in 2021 regarding DehydraTECH’s ability to provide effective solutions for the cardiovascular industryDehydraTECH is being studied for its capacity to improve CBD’s ability to reduce high blood pressure in a rapid and sustainable manner that exceeds the ability of a generic CBD formulationDehydraTECH-CBD underwent three human clinical…